Overall population | MT− | MT+ | p-value# | |
Patients, n | 65 | 14 | 51 | |
Age, years | 54.0 (44.0–59.0) | 44.5 (25.8–50.0) | 57.0 (46.5–60.0) | 0.014 |
BMI, kg·m−2 | 29.4 (26.0–30.0) | 24.7 (22.1–29.7) | 29.7 (27.4–34.5) | 0.008 |
Male, n (%) | 32 (49.2) | 5 (35.7) | 27 (52.9) | 0.40 |
Active smokers, n (%) | 18 (27.7) | 2 (14.3) | 16 (31.4) | 0.35 |
Neck circumference, cm | 40.5 (38.0–43.0) | 37.3 (35.0–41.1) | 41.0 (39.0–43.0) | 0.002 |
STOP-BANG score | 5.0 (3.0–6.0) | 2.5 (2.0–4.8) | 5.0 (4.0–6.0) | 0.003 |
ESS score | 9.0 (5.0–12.0) | 10.5 (6.0–11.0) | 8.0 (4.5–12.0) | 0.89 |
AHI, events·h−1 | 15.6 (5.8–30.7) | 1.9 (0.8–2.3) | 19.5 (13.0–36.3) | <0.001 |
ALAT, U·L−1 | 22.0 (18.0–29.0) | 17.5 (13.3–21.8) | 23.0 (19.5–29.5) | 0.005 |
ASAT, U·L−1 | 22.0 (19.0–26.0) | 20.0 (17.0–23.8) | 22.0 (20.0–26.5) | 0.08 |
FBG, mmol·L−1 | 5.8 (5.3–6.2) | 5.4 (5.1–5.9) | 5.8 (5.4–6.5) | 0.017 |
LDL cholesterol, mmol·L−1 | 3.17 (2.65–3.96) | 2.97 (2.77–3.82) | 3.40 (2.63–3.97) | 0.62 |
HDL cholesterol, mmol·L−1 | 1.21 (0.94–1.41) | 1.37 (1.02–1.69) | 1.10 (0.94–1.40) | 0.067 |
Triglycerides, mmol·L−1 | 1.50 (0.93–2.14) | 0.95 (0.73–1.30) | 1.61 (1.11–2.34) | 0.003 |
β-blocker users, n (%) | 26 (40) | 2 (14.3) | 24 (47.1) | 0.056 |
Data are presented as n, median (interquartile range) or n (%), unless otherwise specified. BMI: body mass index; ESS: Epworth Sleepiness Scale; ALAT: alanine aminotransferase; ASAT: aspartate aminotransferase; FBG: fasting blood glucose; LDL: low-density lipoprotein; HDL: high-density lipoprotein. #: comparisons were done using either Mann–Whitney U-test (for continuous variables) or Pearson's Chi-squared test (for categorical variables) and p-values are reported for differences between the MT− and MT+ groups.